---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Intravenous immunoglobulin"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Intravenous immunoglobulin. Topics: Guideline recommendation in motor CIDP, Immune globulin intravenous versus placebo: adjusted INCAT response through week 24, Pooled randomized evidence for intravenous immunoglobulin, Single-arm induction and maintenance study: responder rate, and 3 further topics. 7 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/intravenous-immunoglobulin"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Intravenous immunoglobulin

<a id="heading-2.2.2.1.2"></a>

## 2.2.2.1.2 Intravenous Immunoglobulin

<a id="topic-2.2.2.1.2-1"></a>

### Guideline recommendation in motor CIDP

> “(c) IVIg should be considered as first-line treatment in motor CIDP (Good Practice Point)”

Source: [Van den Bergh et al. (2021)](https://onlinelibrary.wiley.com/doi/10.1111/ene.14959)

<a id="topic-2.2.2.1.2-2"></a>

### Immune globulin intravenous versus placebo: adjusted INCAT response through week 24

> “117 patients with CIDP who met specific neurophysiological inflammatory neuropathy cause and treatment (INCAT) criteria participated in a randomised, double-blind, placebo-controlled, response-conditional crossover trial.”
> “During the first period, 32 of 59 (54%) patients treated with IGIV-C and 12 of 58 (21%) patients who received placebo had an improvement in adjusted INCAT disability score that was maintained through to week 24 (treatment difference 33.5%, 95% CI 15.4-51.7; p=0.0002).”
> “During the extension phase, participants who continued to receive IGIV-C had a longer time to relapse than did patients treated with placebo (p=0.011).”
> “The incidence of serious adverse events per infusion was 0.8% (9/1096) with IGIV-C versus 1.9% (11/575) with placebo. The most common adverse events with IGIV-C were headache, pyrexia, and hypertension.”

Source: [Hughes et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18178525/)

<a id="topic-2.2.2.1.2-3"></a>

### Pooled randomized evidence for intravenous immunoglobulin

> “We included nine RCTs with 372 participants (235 male) from Europe, North America, South America, and Israel.”
> “IVIg compared with placebo increases the probability of significant improvement in disability within six weeks of the start of treatment (risk ratio (RR) 2.40, 95% confidence interval (CI) 1.72 to 3.36; number needed to treat for an additional beneficial outcome (NNTB) 4, 95% CI 3 to 5; 5 trials, 269 participants; high‐certainty evidence).”
> “During this period, IVIg probably has similar efficacy to oral prednisolone and IVMP.”
> “Further research is needed to assess the long‐term benefits and harms of IVIg relative to other treatments.”

Source: [Bus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10865446/)

<a id="topic-2.2.2.1.2-4"></a>

### Single-arm induction and maintenance study: responder rate

> “Patients received one induction dose of Privigen (2 g/kg body weight [bw]) and up to seven maintenance doses (1 g/kg bw) at 3-week intervals.”
> “The overall responder rate at completion was 60.7% (95% confidence interval [CI]: 42.41%–76.43%).”
> “Two serious AEs of hemolysis were reported that resolved after discontinuation of treatment.”

Source: [Léger et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3910165/)

<a id="topic-2.2.2.1.2-5"></a>

### Maintenance dose-ranging study: response by dose

> “Patients were randomized 1:2:1 to receive the standard intravenous immunoglobulin induction dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks.”
> “The response rate was 80% (55/69 patients) [95% confidence interval (CI): 69–88%] in the 1.0 g/kg group, 65% (22/34; CI: 48–79%) in the 0.5 g/kg group, and 92% (33/36; CI: 78–97%) in the 2.0 g/kg group.”
> “While the proportion of responders was higher with higher maintenance doses, logistic regression analysis showed that the effect on response rate was driven by a significant difference between the 0.5 and 2.0 g/kg groups, whereas the response rates in the 0.5 and 2.0 g/kg groups did not differ significantly from the 1.0 g/kg group.”

Source: [Cornblath et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9050528/)

<a id="topic-2.2.2.1.2-6"></a>

### Rescue treatment of relapse after subcutaneous immunoglobulin or placebo

> “Overall, 20 patients received IVIG 10% ( n = 4 [fSCIG 10%‐relapse group]; n = 16 [placebo‐relapse group]).”
> “Responder rate (95% confidence interval) was 100.0% (80.6%–100.0%) in the placebo‐relapse group and 95.0% (76.4%–99.1%) in the overall‐relapse population.”
> “Across all patients, median time to functional improvement was 25 days.”

Source: [Pasnoor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12006664/)

<a id="topic-2.2.2.1.2-7"></a>

### FDA-approved intravenous immunoglobulin products for CIDP: indications and dosing

> “GAMUNEX-C FlexBag is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.”
> “GAMUNEX-C FlexBag may be initially administered as a total loading dose of 2 g/kg (20 mL/kg) given in divided doses over two to four consecutive days.”
> “GAMUNEX-C FlexBag may be administered as a maintenance infusion of 1 g/kg (10 mL/kg) administered over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on two consecutive days, every 3 weeks.”

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

> “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults (1.3)”
> “Limitations of Use: PRIVIGEN maintenance therapy in CIDP has not been studied beyond 6 months. (1.3)”
> “Loading dose: 2 g/kg (20 mL/kg) in divided doses over 2 to 5 consecutive days Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks”

Source: [Privigen prescribing information (2025)](https://www.fda.gov/media/83304/download)

> “PANZYGA is indicated for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.”
> “Loading dose: 2 g/kg (20 mL/kg), divided into 2 daily doses of 1 g/kg (10 mL/kg) given on 2 consecutive days Maintenance dose: 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days”

Source: [Panzyga prescribing information (2021)](https://www.fda.gov/media/115397/download)

> “Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). (1.3)”
> “Safety and effectiveness of GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP. (1.3)”
> “Induction dose is 2 g/kg in divided doses over 2 to 5 consecutive days, followed by maintenance infusions. Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.”

Source: [Gammagard Liquid prescribing information (2024)](https://www.fda.gov/media/191699/download)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
